95-99%) for patients receiving nonpegylated interferon alfa-2b (with or without Rebetol), and is 99% (95% CI:
95- 99%) neil patsientidel, kes said mitte- pegüleeritud interferooni alfa- 2b (koos Rebetol’ iga või ilma) ja 99% (95% CI: